Effects of antipsychotics on brain insulin action in females: Study protocol for a placebo-controlled, crossover neuroimaging study
PLOS One · 2026
DOI: 10.1371/journal.pone.0352262 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS One, 2026. Verfasst von Nicolette Stogios und 5 weiteren Autor:innen. Beteiligte Einrichtung: Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antipsychotic Agents, Brain, Insulin, Neuroimaging. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMH Womenmind Fund through the Centre for Addiction and Mental Health Foundation.
Abstract (Originalsprache)
Antipsychotic medications can cause serious metabolic adverse effects, including type 2 diabetes, with females disproportionally more affected than males. Recently, brain insulin resistance (IR) has been posited as a potential determinant of these effects. Currently there are no direct methods to investigate brain IR, but physiological response to intranasal insulin (INI) can be used as a surrogate marker. INI reliably suppresses endogenous glucose production and modulates resting-state brain activity in humans; however, the current literature has been heavily focused on males. Recently, it has been reported that hormonal fluctuations throughout the menstrual cycle may influence brain insulin sensitivity. Brain insulin sensitivity is greatest in lean females during the follicular phase, matching that of lean males, but decreases during the luteal phase. This study aims to investigate brain insulin action in females across different phases of the menstrual cycle, and to determine how a metabolically high-risk antipsychotic medication, olanzapine, may disrupt these effects. In a single-blind, crossover design, fifteen female participants aged 18–35 years will undergo a neuroimaging-based assay of brain insulin action with oral olanzapine (or placebo) and intranasal insulin (or placebo) as pharmacological challenges. All treatment conditions will be administered once in each menstrual phase, meaning that each participant receives every condition twice over the course of the study. Two visits will take place during the follicular phase of the menstrual cycle (i.e., cycle days 3–11), and another two visits during the luteal phase (i.e., cycle days 18–25). During each study period, participants will receive either oral olanzapine (OLA) or oral placebo (PL) at doses of 5 mg on Day 0 and 10 mg on Day 1. On Day 2, participants will undergo two MRI scans, the first following intranasal placebo (INP) administration and the second following intranasal insulin (INI). It is hypothesized that INI, but not INP, will modulate resting state brain activity during the follicular menstrual cycle phase but not luteal phase. Oral OLA will subsequently inhibit all INI-induced effects, relative to oral PL, during the follicular phase; OLA will have no apparent effect in the luteal phase given pre-existing brain IR. This is the first study to explore the effect of menstrual cycle phases on the anti-insulin action of antipsychotics. This investigation is necessary for the development of suitable treatment options to minimize the metabolic impact of antipsychotics in females. Trial registration ClinicalTrials.gov Registration: NCT06251635
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
- Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.
- Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
- Margaret and Wallace McCain Centre for Child, Youth & Family Mental Health and Azrieli Adult Neurodevelopmental Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto,…
ORCID-Profile: Nicolette Stogios, Meng-Chuan Lai, Sri Mahavir Agarwal
Förderung
- CAMH Womenmind Fund through the Centre for Addiction and Mental Health Foundation
Zitieren
APA
Stogios, N., Hahn, M. K., Remington, G., Graff-Guerrero, A., Lai, M. C., & Agarwal, S. M. (2026). Effects of antipsychotics on brain insulin action in females: Study protocol for a placebo-controlled, crossover neuroimaging study. PLOS One. https://doi.org/10.1371/journal.pone.0352262
Vancouver
Stogios N, Hahn MK, Remington G, Graff-Guerrero A, Lai MC, Agarwal SM. Effects of antipsychotics on brain insulin action in females: Study protocol for a placebo-controlled, crossover neuroimaging study. PLOS One. 2026. doi:10.1371/journal.pone.0352262
BibTeX
@article{Stogios2026,
author = {Stogios, Nicolette and Hahn, Margaret K and Remington, Gary and Graff-Guerrero, Ariel and Lai, Meng-Chuan and Agarwal, Sri Mahavir},
title = {Effects of antipsychotics on brain insulin action in females: Study protocol for a placebo-controlled, crossover neuroimaging study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0352262}
}
EUVIMED